Intensity Therapeutics resumes breast cancer trial in Switzerland

July 15, 2026 7:45 AM

Intensity Therapeutics, Inc. (Nasdaq: INTS) announced July 15 that it has resumed patient dosing in its INVINCIBLE-4 Study, a Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found